{"id":61810,"date":"2025-09-03T10:05:36","date_gmt":"2025-09-03T08:05:36","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/medable-launches-the-industrys-first-agentic-ai-platform-and-cra-agent-removes-bottlenecks-in-clinical-development\/"},"modified":"2025-09-03T10:05:36","modified_gmt":"2025-09-03T08:05:36","slug":"medable-launches-the-industrys-first-agentic-ai-platform-and-cra-agent-removes-bottlenecks-in-clinical-development","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/medable-launches-the-industrys-first-agentic-ai-platform-and-cra-agent-removes-bottlenecks-in-clinical-development\/","title":{"rendered":"Medable Launches The Industry\u2019s First Agentic AI Platform and CRA Agent; Removes Bottlenecks in Clinical Development"},"content":{"rendered":"
\n

\nAgent Studio marks a turning point in clinical research, moving from human-heavy processes to scalable agents that streamline work and accelerate trials<\/i><\/p>\n

PALO ALTO, Calif.–(BUSINESS WIRE)–Medable, the leading technology provider for clinical development, today launched Agent Studio<\/a>: the industry\u2019s first agentic AI platform purpose-built for life sciences. Agent Studio is a no-code agent-builder that enables clinical teams to quickly custom-configure AI agents. Medable also introduced CRA Agent<\/a>, an out-of-the-box agent running on Agent Studio that is specifically designed for clinical trial monitoring. Both Agent Studio and CRA Agent will drive unprecedented efficiencies across the clinical development life cycle and remove bottlenecks hindering scientific advancement.<\/p>\n

<\/a>
<\/a><\/p>\n

\nDespite decades of innovation, clinical development remains constrained by persistent operational inefficiencies that slow progress. New drugs spend about 45%<\/a> of development time on white space, the unproductive time in trial phases. Agent Studio not only removes white space between phases but also the longstanding bottlenecks anchoring trial processes.<\/p>\n

\nMedable\u2019s new Agent Studio empowers teams to create purpose-fit agents that solve key clinical development bottlenecks to eliminate white space across complex trial workflows such as protocol development and trial planning and optimization.<\/p>\n

\n\u201cAgent Studio is more than just technology \u2013 it\u2019s a catalyst to unleash greater human potential in life sciences,\u201d said Dr. Michelle Longmire, CEO and co-founder of Medable. \u201cIt frees teams from the bottlenecks of legacy systems, accelerates trials, reduces costs, and ultimately helps bring medicines to patients faster. We believe this is a once-in-a-generation leap forward in how clinical research gets done.\u201d<\/p>\n

\nAgent Studio is an expansion of Medable\u2019s award-winning platform<\/a> that drives eCOA, decentralized trial execution, and AI\u2011driven study design, including the following key advantages:<\/p>\n